ADMA Biologics, Inc. (ADMA)

8,81 +1,88 (+27,13%) Al cierre: 04:00PM EDT

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
https://www.admabiologics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 624

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Adam S. Grossman	Co-Founder, President, CEO, Interim CFO & Director	1,59M	N/A	1977
Dr. Jerrold B. Grossman D.P.S., Ph.D.	Co-Founder & Vice Chairman of the Board	90k	N/A	1948
Ms. Kaitlin Kestenberg	COO & Senior VP of Compliance	N/A	N/A	1987
Mr. Drew Pantello	Vice President of Marketing & Corporate Development	N/A	N/A	N/A
Ms. Cindy Petersen	Executive Director of Human Resources	N/A	N/A	N/A
Mr. Skyler Bloom	Senior Director of Business Development & Corporate Strategy	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de ADMA Biologics, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 7; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.